Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

39 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Model-based meta-analysis using latent variable modeling to set benchmarks for new treatments of systemic lupus erythematosus.
Goteti K, Garcia R, Gillespie WR, French J, Klopp-Schulze L, Li Y, Mateo CV, Roy S, Guenther O, Benincosa L, Venkatakrishnan K. Goteti K, et al. Among authors: guenther o. CPT Pharmacometrics Syst Pharmacol. 2024 Feb;13(2):281-295. doi: 10.1002/psp4.13083. Epub 2023 Dec 4. CPT Pharmacometrics Syst Pharmacol. 2024. PMID: 38050332 Free PMC article.
Towards a novel clinical outcome assessment for systemic lupus erythematosus: first outcomes of an international taskforce.
Connelly K, Eades LE, Koelmeyer R, Ayton D, Golder V, Kandane-Rathnayake R, Gregory K, Brunner H, Burke L, Arnaud L, Askanase A, Aranow C, Vital E, Pons-Estel G, Dantata K, Andersen J, Cornet A, Buie J, Sun Y, Tanaka Y, Simon L, Lahoud Y, Friedman A, Kalunian K, Zuraw Q, Werth V, Garces S, Morand EF; TRM-SLE Consortium. Connelly K, et al. Nat Rev Rheumatol. 2023 Sep;19(9):592-602. doi: 10.1038/s41584-023-00993-7. Epub 2023 Jul 11. Nat Rev Rheumatol. 2023. PMID: 37433880 Review.
Disease trajectory of SLE clinical endpoints and covariates affecting disease severity and probability of response: Analysis of pooled patient-level placebo (Standard-of-Care) data to enable model-informed drug development.
Goteti K, French J, Garcia R, Li Y, Casset-Semanaz F, Aydemir A, Townsend R, Mateo CV, Studham M, Guenther O, Kao A, Gastonguay M, Girard P, Benincosa L, Venkatakrishnan K. Goteti K, et al. Among authors: guenther o. CPT Pharmacometrics Syst Pharmacol. 2023 Feb;12(2):180-195. doi: 10.1002/psp4.12888. Epub 2022 Nov 29. CPT Pharmacometrics Syst Pharmacol. 2023. PMID: 36350330 Free PMC article.
Response letter to the Editor.
Conaghan PG, Guehring H, Moreau F, Daelken B, Ladel C, Guenther O, Reinstrup Bihlet A, Wirth W, Eckstein F, Hochberg M. Conaghan PG, et al. Among authors: guenther o. Semin Arthritis Rheum. 2022 Feb;52:151839. doi: 10.1016/j.semarthrit.2021.05.001. Epub 2021 May 8. Semin Arthritis Rheum. 2022. PMID: 34006385 Free article. No abstract available.
Long-term structural and symptomatic effects of intra-articular sprifermin in patients with knee osteoarthritis: 5-year results from the FORWARD study.
Eckstein F, Hochberg MC, Guehring H, Moreau F, Ona V, Bihlet AR, Byrjalsen I, Andersen JR, Daelken B, Guenther O, Ladel C, Michaelis M, Conaghan PG. Eckstein F, et al. Among authors: guenther o. Ann Rheum Dis. 2021 Aug;80(8):1062-1069. doi: 10.1136/annrheumdis-2020-219181. Epub 2021 May 7. Ann Rheum Dis. 2021. PMID: 33962962 Free PMC article. Clinical Trial.
The effects of sprifermin on symptoms and structure in a subgroup at risk of progression in the FORWARD knee osteoarthritis trial.
Guehring H, Moreau F, Daelken B, Ladel C, Guenther O, Bihlet AR, Wirth W, Eckstein F, Hochberg M, Conaghan PG. Guehring H, et al. Among authors: guenther o. Semin Arthritis Rheum. 2021 Apr;51(2):450-456. doi: 10.1016/j.semarthrit.2021.03.005. Epub 2021 Mar 11. Semin Arthritis Rheum. 2021. PMID: 33752164 Free article. Clinical Trial.
[THE DEVELOPMENT OF IMMUNITY].
GUENTHER O. GUENTHER O. Dtsch Med Wochenschr. 1964 Dec 25;89:2449-54. doi: 10.1055/s-0028-1113302. Dtsch Med Wochenschr. 1964. PMID: 14223823 German. No abstract available.
39 results